EXECUTIVE ENGAGEMENTS
POOL
6789
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1086
Interactions with Platform & by Email
PARTICIPANTS
204
Unique # Participated
VALIDATIONS
92
Responses Validated*
COMPANIES
43
Responses Validated*
* Login for a full stack data experience
DATE
APR 2021
TABLES
66
PAGES
139
EDITION
8
PRICE
USD 4950
CODE
MCP13152
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Malignant Mesothelioma estimated at US$379.2 Million in the year 2020, is projected to reach a revised size of US$574.6 Million by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027. Premetrexed and combination, one of the segments analyzed in the report, is projected to record a 6.7% CAGR and reach US$302.7 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cisplatin and combination segment is readjusted to a revised 6% CAGR for the next 7-year period.
The Malignant Mesothelioma market in the U.S. is estimated at US$112 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$100.7 Million by the year 2027 trailing a CAGR of 5.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 4.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.
In the global Carboplatin and combination segment, USA, Canada, Japan, China and Europe will drive the 5.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$40.4 Million in the year 2020 will reach a projected size of US$59.8 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$65.9 Million by the year 2027.
SELECT PLAYERS
AstraZeneca PLC; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Concordia International Corporation; Corden Pharma International GmbH; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fresenius Kabi AG; Kyowa Hakko Kirin Co., Ltd.; Merck & Co., Inc.; MolMed S.p.A.; Mylan NV; Nichi-Iko Pharmaceutical Co., Ltd.; Novartis International AG; Ono Pharmaceutical Co., Ltd.; Pfizer, Inc.; Polaris Pharmaceuticals, Inc.; Sanofi S.A.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» Drug Class (Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination, Other Combinations)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Malignant Mesothelioma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Premetrexed and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Premetrexed and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Cisplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Cisplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Carboplatin and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Carboplatin and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Gemcitabine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Gemcitabine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Vinorelbine and combination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Vinorelbine and combination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Combinations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Combinations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Malignant Mesothelioma by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Malignant Mesothelioma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Malignant Mesothelioma by Drug Class - Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Malignant Mesothelioma by Drug Class - Percentage Breakdown of Value Sales for Premetrexed and combination, Cisplatin and combination, Carboplatin and combination, Gemcitabine and combination, Vinorelbine and combination and Other Combinations for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 43 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com